Recent from talks
AL-LAD
Knowledge base stats:
Talk channels stats:
Members stats:
AL-LAD
AL-LAD, or ALLAD, also known as ALLY-LAD or as 6-allyl-6-nor-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is taken orally.
The drug interacts with serotonin and dopamine receptors and is known to act as an agonist of the serotonin 5-HT2A receptor similarly to LSD. AL-LAD produces psychedelic-like effects in animals. It is closely structurally related to LSD and to other psychedelic lysergamides such as ETH-LAD and PRO-LAD.
AL-LAD was first described in the scientific literature by 1976. Subsequently, it was described by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines i Have Known And Loved). AL-LAD was encountered as a novel designer recreational drug by 2015. The related drugs 1P-AL-LAD, 1cP-AL-LAD, and 1T-AL-LAD are thought to function as prodrugs of AL-LAD and have also been encountered as designer drugs in the 2020s.
In his book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin describes the dose range of AL-LAD as 80 to 160 μg and its duration as 6 to 8 hours. In other publications however, Shulgin listed its dose range as 50 to 150 μg. A typical or moderate dose may be around 100 μg. The drug appears to be roughly equipotent with LSD, which has a listed dose range of 50 to 200 μg. AL-LAD's duration appears to be shorter than that of LSD, which is said to have a duration of 8 to 12 hours. The onset of AL-LAD has been reported to be within 15 to 20 minutes, but others reported a slower and more gradual onset building up over a few hours. It is also reported to have a very long "down-ramp" of effects.
AL-LAD has been described as producing similar effects to LSD and as being "really trippy" similarly, but as lacking the "vaguely sinister push" of LSD. In addition, it has been reported to have less visual distortion than LSD. The experience has been described as "simply beautiful". Its effects have been reported to include waves of intensification, no closed-eye visuals to superb mental imagery, mild visual distortion, open-eye visuals including floors melting and patterns on walls and ceilings flowing, some time dilation, separation from surrounding world, loss of contact with body, body feeling "blob-like", feeling stoned, music and erotic enhancement, clear thinking and good interpretation, mental and physical excitation, mood fluctuations, emotional lability, crying, opening up of repressed feelings, and in one case social distance and avoidance. Some individuals specifically reported no fear, panic, or body disturbance.
AL-LAD has been found to interact with the serotonin 5-HT1 and 5-HT2 receptors and with the dopamine D1 and D2 receptors. It is known to act as a potent full agonist of the serotonin 5-HT2A receptor.
The drug was about 3.5-fold more potent than LSD in substituting for LSD in drug discrimination tests in rodents. Conversely however, AL-LAD was similar in potency to LSD in humans. AL-LAD produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents. It was slightly less potent than LSD in producing the head-twitch response in rodents.
The in-vitro metabolism of AL-LAD has been studied.
Hub AI
AL-LAD AI simulator
(@AL-LAD_simulator)
AL-LAD
AL-LAD, or ALLAD, also known as ALLY-LAD or as 6-allyl-6-nor-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is taken orally.
The drug interacts with serotonin and dopamine receptors and is known to act as an agonist of the serotonin 5-HT2A receptor similarly to LSD. AL-LAD produces psychedelic-like effects in animals. It is closely structurally related to LSD and to other psychedelic lysergamides such as ETH-LAD and PRO-LAD.
AL-LAD was first described in the scientific literature by 1976. Subsequently, it was described by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines i Have Known And Loved). AL-LAD was encountered as a novel designer recreational drug by 2015. The related drugs 1P-AL-LAD, 1cP-AL-LAD, and 1T-AL-LAD are thought to function as prodrugs of AL-LAD and have also been encountered as designer drugs in the 2020s.
In his book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin describes the dose range of AL-LAD as 80 to 160 μg and its duration as 6 to 8 hours. In other publications however, Shulgin listed its dose range as 50 to 150 μg. A typical or moderate dose may be around 100 μg. The drug appears to be roughly equipotent with LSD, which has a listed dose range of 50 to 200 μg. AL-LAD's duration appears to be shorter than that of LSD, which is said to have a duration of 8 to 12 hours. The onset of AL-LAD has been reported to be within 15 to 20 minutes, but others reported a slower and more gradual onset building up over a few hours. It is also reported to have a very long "down-ramp" of effects.
AL-LAD has been described as producing similar effects to LSD and as being "really trippy" similarly, but as lacking the "vaguely sinister push" of LSD. In addition, it has been reported to have less visual distortion than LSD. The experience has been described as "simply beautiful". Its effects have been reported to include waves of intensification, no closed-eye visuals to superb mental imagery, mild visual distortion, open-eye visuals including floors melting and patterns on walls and ceilings flowing, some time dilation, separation from surrounding world, loss of contact with body, body feeling "blob-like", feeling stoned, music and erotic enhancement, clear thinking and good interpretation, mental and physical excitation, mood fluctuations, emotional lability, crying, opening up of repressed feelings, and in one case social distance and avoidance. Some individuals specifically reported no fear, panic, or body disturbance.
AL-LAD has been found to interact with the serotonin 5-HT1 and 5-HT2 receptors and with the dopamine D1 and D2 receptors. It is known to act as a potent full agonist of the serotonin 5-HT2A receptor.
The drug was about 3.5-fold more potent than LSD in substituting for LSD in drug discrimination tests in rodents. Conversely however, AL-LAD was similar in potency to LSD in humans. AL-LAD produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents. It was slightly less potent than LSD in producing the head-twitch response in rodents.
The in-vitro metabolism of AL-LAD has been studied.
Recent media